RecruitingEarly Phase 1NCT06387381

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Sponsor

First Affiliated Hospital of Chongqing Medical University

Enrollment

30 participants

Start Date

May 20, 2024

Study Type

INTERVENTIONAL

Conditions

Positron Emission Tomography FAP PSMA

Summary

As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

At least 18 years of age.
Signed informed consent.
Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).

Exclusion Criteria5

Patients with non-malignant disease.
Patients with pregnancy.
The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Known or expected hypersensitivity to 68Ga-PSFA or any of its components.
Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Interested in this trial?

Get notified about updates and connect with the research team.